Taysha Gene Therapies Stock Performance
| TSHA Stock | USD 3.24 0.24 8.00% |
On a scale of 0 to 100, Taysha Gene holds a performance score of 9. The entity has a beta of 2.25, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Taysha Gene will likely underperform. Please check Taysha Gene's downside variance, daily balance of power, period momentum indicator, as well as the relationship between the skewness and day typical price , to make a quick decision on whether Taysha Gene's existing price patterns will revert.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Taysha Gene Therapies are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak technical indicators, Taysha Gene sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 8 | Five Day Return 9.09 | Year To Date Return 89.47 | Ten Year Return (86.53) | All Time Return (86.53) |
1 | Taysha Gene Therapies SWOT analysis promising rett syndrome therapy drives stock potential - Investing.com | 09/30/2024 |
2 | Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635 | 10/04/2024 |
3 | Acquisition by Nagendran Sukumar of 790093 shares of Taysha Gene subject to Rule 16b-3 | 10/18/2024 |
4 | Piper Sandler expects Taysha Gene to recover, maintains 7 shares target | 11/12/2024 |
5 | FMR LLCs Strategic Reduction in Taysha Gene Therapies Inc | 11/13/2024 |
6 | Taysha Gene Therapies Price Target Raised to 8.00 at Canaccord Genuity Group | 11/15/2024 |
7 | Taysha Gene Therapies SWOT analysis stock poised for growth in Rett syndrome market | 11/26/2024 |
| Begin Period Cash Flow | 90.5 M |
Taysha |
Taysha Gene Relative Risk vs. Return Landscape
If you would invest 206.00 in Taysha Gene Therapies on September 3, 2024 and sell it today you would earn a total of 118.00 from holding Taysha Gene Therapies or generate 57.28% return on investment over 90 days. Taysha Gene Therapies is currently generating 0.9828% in daily expected returns and assumes 7.9678% risk (volatility on return distribution) over the 90 days horizon. In different words, 70% of stocks are less volatile than Taysha, and 81% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Taysha Gene Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Taysha Gene's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Taysha Gene Therapies, and traders can use it to determine the average amount a Taysha Gene's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1234
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TSHA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.97 actual daily | 70 70% of assets are less volatile |
Expected Return
| 0.98 actual daily | 19 81% of assets have higher returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average Taysha Gene is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Taysha Gene by adding it to a well-diversified portfolio.
Taysha Gene Fundamentals Growth
Taysha Stock prices reflect investors' perceptions of the future prospects and financial health of Taysha Gene, and Taysha Gene fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Taysha Stock performance.
| Return On Equity | -1.15 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (2.30) % | ||||
| Operating Margin | (11.78) % | ||||
| Current Valuation | 568.87 M | ||||
| Shares Outstanding | 204.94 M | ||||
| Price To Book | 7.48 X | ||||
| Price To Sales | 66.97 X | ||||
| Revenue | 15.45 M | ||||
| Gross Profit | 2.5 M | ||||
| EBITDA | (105.2 M) | ||||
| Net Income | (111.57 M) | ||||
| Cash And Equivalents | 66.24 M | ||||
| Cash Per Share | 1.61 X | ||||
| Total Debt | 61.11 M | ||||
| Debt To Equity | 1.93 % | ||||
| Current Ratio | 1.79 X | ||||
| Book Value Per Share | 0.33 X | ||||
| Cash Flow From Operations | (73.02 M) | ||||
| Earnings Per Share | 0.63 X | ||||
| Market Capitalization | 664.02 M | ||||
| Total Asset | 172.73 M | ||||
| Retained Earnings | (513.01 M) | ||||
| Working Capital | 113.11 M | ||||
About Taysha Gene Performance
By analyzing Taysha Gene's fundamental ratios, stakeholders can gain valuable insights into Taysha Gene's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Taysha Gene has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Taysha Gene has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.65) | (0.68) | |
| Return On Capital Employed | (0.53) | (0.51) | |
| Return On Assets | (0.65) | (0.68) | |
| Return On Equity | (1.49) | (1.56) |
Things to note about Taysha Gene Therapies performance evaluation
Checking the ongoing alerts about Taysha Gene for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Taysha Gene Therapies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Taysha Gene is way too risky over 90 days horizon | |
| Taysha Gene appears to be risky and price may revert if volatility continues | |
| Taysha Gene has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 15.45 M. Net Loss for the year was (111.57 M) with profit before overhead, payroll, taxes, and interest of 2.5 M. | |
| Taysha Gene Therapies currently holds about 66.24 M in cash with (73.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.61. | |
| Over 77.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: 104,535 Shares in Terns Pharmaceuticals, Inc. Purchased by Quest Partners LLC - MarketBeat |
- Analyzing Taysha Gene's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Taysha Gene's stock is overvalued or undervalued compared to its peers.
- Examining Taysha Gene's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Taysha Gene's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Taysha Gene's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Taysha Gene's stock. These opinions can provide insight into Taysha Gene's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Taysha Stock analysis
When running Taysha Gene's price analysis, check to measure Taysha Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Taysha Gene is operating at the current time. Most of Taysha Gene's value examination focuses on studying past and present price action to predict the probability of Taysha Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Taysha Gene's price. Additionally, you may evaluate how the addition of Taysha Gene to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |